Aimmune To Present At The Bank of America Merrill Lynch 2016 Health Care Conference

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that Stephen G. Dilly, M.B.B.S., Ph.D., Chief Executive Officer of Aimmune, will present a company overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada, on Wednesday, May 11, 2016, at 11:20 a.m. Pacific Time.